Geno10X Biosciences
AI-enabled medical device startup developing a rapid, non-invasive testing platform that combines urine-based molecular assays, advanced imaging sensors, and machine learning to predict disease risk at point of care. The company focuses on decentralized testing stations, assay materials (dyes/quantum dots), and partnerships with research labs and distribution networks.
Industries
Nr. of Employees
small (1-50)
Products
Rapid non-invasive urine biomarker testing platform
A testing platform that uses urine samples and fluorescence-based assays, combined with imaging sensors and AI analysis, to predict disease risk without PCR.
Decentralized point-of-care testing stations
Modular POCT stations intended for near-patient testing to enable rapid sample processing and easy-to-interpret results.
AI-enabled digital health platform for triage
Software platform that integrates test results with AI models to identify patients in need of advanced care and streamline the care journey.
Rapid non-invasive urine biomarker testing platform
A testing platform that uses urine samples and fluorescence-based assays, combined with imaging sensors and AI analysis, to predict disease risk without PCR.
Decentralized point-of-care testing stations
Modular POCT stations intended for near-patient testing to enable rapid sample processing and easy-to-interpret results.
AI-enabled digital health platform for triage
Software platform that integrates test results with AI models to identify patients in need of advanced care and streamline the care journey.
Services
R&D collaborations and licensing
Partnering with research laboratories to license and co-develop technologies for rapid DNA and protein detection.
POCT deployment and distribution partnerships
Working with distribution partners and healthcare networks to deploy decentralized testing stations and scale access.
AI algorithm development and integration
Development and integration of custom AI algorithms for analysis of assay outputs and risk prediction within a digital health platform.
R&D collaborations and licensing
Partnering with research laboratories to license and co-develop technologies for rapid DNA and protein detection.
POCT deployment and distribution partnerships
Working with distribution partners and healthcare networks to deploy decentralized testing stations and scale access.
AI algorithm development and integration
Development and integration of custom AI algorithms for analysis of assay outputs and risk prediction within a digital health platform.
Expertise Areas
- AI-driven diagnostics
- Digital health platform development
- Urine biomarker assay development
- Fluorescence and quantum dot-based assays
Key Technologies
- Machine learning for diagnostic prediction
- Quantum dot and fluorescent dye labelling
- Next-generation imaging sensors
- Non-PCR molecular detection methods